Enabling scalable CAR-T therapies with next-gen animal component-free T cell media

Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Enabling scalable CAR-T therapies with next-gen animal component-free T cell media

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

Animal component-free (ACF) cell culture media can improve consistency, safety, and regulatory compliance in CAR-T cell manufacturing. Attend this webinar for insights into how ACF media perform in both static and stirred systems, enabling more flexible and scalable manufacturing workflows for both autologous and allogeneic CAR-T therapies.

The effectiveness of two ACF media formulations will be evaluated in comparison to alternative ACF and xeno-free options, demonstrating how CAR-T cells cultured in ACF media maintained robust CAR expression over time, supporting long-term functionality. Additionally, the CAR-T cells demonstrated specific cytotoxicity against target cells, with a majority exhibiting a less differentiated phenotype, which is often associated with better persistence and efficacy in vivo.

Attendees will gain an understanding in the shift towards animal-free, closed-system cell culture and how next-generation media solutions align with evolving standards in commercial CAR-T production.

Attend this webinar to:

• Discover the limitations and potential safety concerns of using serum and other animal-derived supplements in T cell culture, and gain the knowledge and confidence to transition to ACF media

• Learn how ACF media can reduce safety and contamination risks and eliminate lot-to-lot variability, improving the safety and reproducibility of CAR-T cell products

• Gain insights on how to apply data-driven strategies to maintain robust CAR expression and promote less differentiated, functional T cells, improving therapeutic potential and persistence

• Explore how to achieve robust CAR expression and functional T cells for CAR-T cell manufacturing

Pedro Azevedo Da Silva Couto

Research Fellow at UCL

Pedro Silva Couto is a Postdoctoral Research Fellow in Biochemical Engineering at University College London (UCL), specialising in the scalable manufacturing of advanced cell and gene therapies. His work focuses on closed and intensified bioprocesses for CART cells and mesenchymal stromal cells (MSC), exploring how medium formulation, cytokine combinations and physical parameters influence cell growth, phenotype and function. He has a particular interest in scaleup strategies that translate small scale studies into clinically relevant processes, and in optimising gene delivery methods such as viral transduction to improve efficiency. Through this research, Pedro aims to enable cost effective, robust production platforms that accelerate the translation of cell and gene therapies.

Rukmini Ladi

Segment Technology Manager at Sartorius

Rukmini is a Bioprocess Development Engineer with over 10 years of experience in cell and gene therapy. As the Segment Technology Manager for Cell Therapy at Sartorius, she drives the segment vision and provides process expertise to support cell therapy developers in building end-to-end workflows using Sartorius' comprehensive solutions. Additionally, she leads strategic partnerships with industry leaders and academic partners, fostering collaboration to deliver innovative solutions that advance the field of cell therapy.

You have registered for this webinar